Clinical Study

Blood Pressure Response to Zofenopril or Irbesartan Each Combined with Hydrochlorothiazide in High-Risk Hypertensives Uncontrolled by Monotherapy: A Randomized, Double-Blind, Controlled, Parallel Group, Noninferiority Trial

Table 2

Baseline-adjusted office systolic blood pressure (SBP) and diastolic blood pressure (DBP) reductions after 18 weeks of treatment with zofenopril + hydrochlorothiazide (HCTZ) or irbesartan + HCTZ in the whole study group and in the subgroup of patients treated with the low drug dose (zofenopril 30 mg or irbesartan 150 mg). Data are shown for the intention-to-treat population and reported as mean ± SD or as mean and 95% confidence interval. The value refers to the statistical significance of the intertreatment difference.

OfficeSBPDBP
Zofenopril 30–60 mg + HCTZ 12.5 mgIrbesartan 150–300 mg + HCTZ 12.5 mgZofenopril 30–60 mg + HCTZ 12.5 mgIrbesartan 150–300 mg + HCTZ 12.5 mg

All subjects
 Baseline (mmHg)148.4 ± 9.6149.3 ± 10.191.6 ± 6.791.6 ± 6.8
 Reduction with treatment (mmHg)15.7 (13.9, 17.5)19.3 (17.5, 21.1)8.6 (7.4, 9.8)11.6 (10.4, 12.8)
value0.001<0.001
Low dose subgroup
 Baseline (mmHg)147.4 ± 9.5147.4 ± 8.390.4 ± 6.891.4 ± 6.7
 Reduction with treatment (mmHg)19.5 (18.0, 21.0)22.5 (20.7, 24.3)12.7 (11.0, 14.4)15.2 (13.8, 16.6)
value0.0650.096